These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 25535814)
1. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation. Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814 [TBL] [Abstract][Full Text] [Related]
2. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma. Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672 [TBL] [Abstract][Full Text] [Related]
3. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells. Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells. Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359 [TBL] [Abstract][Full Text] [Related]
5. B-cell receptor signaling in diffuse large B-cell lymphoma. Young RM; Shaffer AL; Phelan JD; Staudt LM Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587 [TBL] [Abstract][Full Text] [Related]
6. c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells. David A; Arnaud N; Fradet M; Lascaux H; Ouk-Martin C; Gachard N; Zimber-Strobl U; Feuillard J; Faumont N Haematologica; 2017 May; 102(5):883-894. PubMed ID: 28232371 [TBL] [Abstract][Full Text] [Related]
7. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532 [TBL] [Abstract][Full Text] [Related]
8. MiR-17∼92 is involved in NF-κB activation via targeting the ubiquitin-editing proteins to mediate RIP1 complex polyubiquitinations in ABC-DLBCL. Zhang X; Zhang X; Huang X; Iqbal J; McKeithan TW; Chan WC; Vose JM; Bi C; Zhu X; Fu K Clin Immunol; 2024 Aug; 265():110297. PubMed ID: 38909971 [TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311 [TBL] [Abstract][Full Text] [Related]
10. Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. Gamboa-Cedeño AM; Castillo M; Xiao W; Waldmann TA; Ranuncolo SM J Cancer Res Clin Oncol; 2019 Jun; 145(6):1437-1448. PubMed ID: 30941572 [TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134 [TBL] [Abstract][Full Text] [Related]
12. The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy. Liu H; Wei J; Sang N; Zhong X; Zhou X; Yang X; Zhang J; Zuo Z; Zhou Y; Yang S; Du J; Zhao Y Med Oncol; 2021 Sep; 38(10):124. PubMed ID: 34491469 [TBL] [Abstract][Full Text] [Related]
13. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression. Zhang B; Calado DP; Wang Z; Fröhler S; Köchert K; Qian Y; Koralov SB; Schmidt-Supprian M; Sasaki Y; Unitt C; Rodig S; Chen W; Dalla-Favera R; Alt FW; Pasqualucci L; Rajewsky K Cell Rep; 2015 May; 11(5):715-26. PubMed ID: 25921526 [TBL] [Abstract][Full Text] [Related]
14. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma. Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J Leuk Lymphoma; 2024 Jul; 65(7):895-910. PubMed ID: 38497543 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma. Plotnik JP; Richardson AE; Yang H; Rojas E; Bontcheva V; Dowell C; Parsons S; Wilson A; Ravanmehr V; Will C; Jung P; Zhu H; Partha SK; Panchal SC; Mali RS; Kohlhapp FJ; McClure RA; Ramathal CY; George MD; Jhala M; Elsen NL; Qiu W; Judge RA; Pan C; Mastracchio A; Henderson J; Meulbroek JA; Green MR; Pappano WN Mol Cancer Ther; 2024 Jul; 23(7):949-960. PubMed ID: 38507740 [TBL] [Abstract][Full Text] [Related]
16. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma. Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447 [TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185 [TBL] [Abstract][Full Text] [Related]
18. SENP1 knockdown potentiates the apoptosis, cell cycle arrest, and reduces cisplatin resistance of diffuse large B cell lymphoma cells via inducing ferroptosis. Dong J; Zheng X Biochem Cell Biol; 2024 Aug; 102(4):319-330. PubMed ID: 38708853 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma. Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828 [TBL] [Abstract][Full Text] [Related]
20. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790 [No Abstract] [Full Text] [Related] [Next] [New Search]